Genzyme: Icahn's interest does not signal merger

Genzyme Corp. insists that investor Carl Icahn's interest in the company will not prompt a takeover. "To integrate us to into a very large entity is not that attractive. [The company] is much stronger as it is right now -- as a stand-alone rather than as part of a company 10 times our size," chief executive Henri Termeer said in an interview.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA